Indian Govt Lifts Export Ban on Anti-malarial Drug Hydroxychloroquine

India has lifted the restriction on the export of anti-malarial drug Hydroxychloroquine, which is broadly used around the world as a prophylactic to fight novel coronavirus.

India has lifted the export ban on hydroxychloroquine, an anti-malarial drug with immediate effect. On March 25, the government banned the export of the drug due to the outbreak of the COVID-19 pandemic.

The Centre had imposed curbs on the export of Hydroxychloroquine and formulations used to manufacture the medicine.

ICMR Recommends Hydroxychloroquine Use in Emergency Situations
Guidelines for the use of Hydroxychloroquine (HCQ) have been revised by the ICMR advisory. An in-vitro testing of HCQ for antiviral efficacy showed reduction of infection in SARS-CoV2 patients.

‘India is a major exporter of Hydroxychloroquine drug, which has witnessed a surge in demand amid the novel COVID-19 crisis. ’
Read More..

According to a late-night notification by the Ministry of Commerce and Industry, the export status of the medication and the composition ingredients have been changed from "prohibited" to "free."

The notification was issued by the Directorate General of Foreign Trade (DGFT).

Source-IANS

COVID-19: Hydroxychloroquine Trial Begins in the UK
COVID-19 vaccine trial with two antimalarial drugs - chloroquine and hydroxychloroquine has begun in the UK's Brighton and Oxford. The trial is open to anyone delivering direct care to coronavirus patients in the UK.

Recent Review Casts Doubt on Use of Chloroquine and Hydroxychloroquine for COVID-19 Patients
The FASEB Journal: New clinical review casts doubt on use of chloroquine and hydroxychloroquine for patients with COVID-19.

COVID-19: India Partially Lifts Ban on Export of Hydroxychloroquine and Paracetamol
Coronavirus: India partially lifts ban on export of hydroxychloroquine (HCQ) and paracetamol after Donald Trump's retaliation warning.